Prophylactic Antiparkinson Drug Use: II. Withdrawal After Long‐Term Maintenance Therapy
- 1 August 1991
- journal article
- review article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 31 (8) , 769-777
- https://doi.org/10.1002/j.1552-4604.1991.tb03775.x
Abstract
Although the efficacy of long‐term neuroleptic treatment of schizophrenic patients is generally accepted, the use of concurrent antiparkinson drugs is less well defined. The value of prolonged antiparkinson drug use in preventing extrapyramidal side effects is controversial. More than 30 studies of antiparkinson drug withdrawal have attempted to answer this question. The authors reviewed all double‐blind, placebo‐controlled studies, and found most to contain serious methodologic or statistical flaws. There is evidence to support the long‐term use of these agents in preventing extrapyramidal side effects. The authors offer an analysis of the benefits and risks that are involved with prophylactic antiparkinson drug use, and conclude that most patients would benefit from maintenance therapy.Keywords
This publication has 36 references indexed in Scilit:
- ABNORMAL INVOLUNTARY MOVEMENTS INDUCED BY ANTICHOLINERGIC THERAPYActa Neurologica Scandinavica, 2009
- Prophylactic Antiparkinson Drug Use: I. Initial Prophylaxis and Prevention of Extrapyramidal Side EffectsThe Journal of Clinical Pharmacology, 1991
- Tardive DyskinesiaJournal of Clinical Psychopharmacology, 1988
- Comparing the Means of Several GroupsNew England Journal of Medicine, 1985
- Discontinuing antiparkinson medication in chronic schizophrenicsActa Psychiatrica Scandinavica, 1981
- Extrapyramidal effects of neuroleptics.Journal of Neurology, Neurosurgery & Psychiatry, 1976
- Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentrations and effects in man.British Journal of Clinical Pharmacology, 1975
- Benzhexol and Side Effects with Long-acting Fluphenazine TherapyBMJ, 1972
- Antiparkinson Drug OverusePsychosomatics, 1970